会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Thromboxane ligands without blood clotting side effects
    • 血凝素配体无凝血副作用
    • US06462077B1
    • 2002-10-08
    • US09899713
    • 2001-07-05
    • Robert M. BurkAchim H-P KraussDavid F. Woodward
    • Robert M. BurkAchim H-P KraussDavid F. Woodward
    • C07D30793
    • C07D307/00A61K31/558C07D319/08C07D493/08
    • A method of treating ocular hypotension, hypertension, hemorrhage, myocardial ischemia, angina pectoris, coronary contraction, cerebrovascular contraction after subarachnoidal hemorrhage, cerebral hemorrhage and asthma which comprises administering to a mammal suffering therefrom a therapeutically effective amount of a thromboxane ligand which is a compound formula I, wherein Y is (CH2)x; Z is selected from the group consisting of O, OCH2, and (CR2)x, x is an integer of 1 or 2; n is 0 or 1; R2 is hydrogen or an alkyl radical of from 1 to 4 carbons; A is an alkylene or alkenylene radical having from two to seven carbon atoms, which radical may be substituted with one or more hydroxy, oxo, alkyloxy or alkylcarboxy groups or said alkylene or alkenylene may have one or more enchained oxa or imino radicals; B is a methyl radical or a cycloalkyl radical having from three to seven carbon atoms, or an aryl radical, selected from the group consisting of hydrocarbyl aryl and heteroaryl radicals wherein the heteroatom is selected from the group consisting of nitrogen, oxygen and sulfur atoms, or substituted derivatives of said methyl, cycloalkyl or aryl radicals wherein said substituent is selected from the group consisting of halo, nitro, amino, thiol, hydroxy, alkyloxy and alkylcarboxy; and X is selected from the group consisting of nitro, cyano, —COOR, —CH2OR1, —C(O)N(R1)2, —CH2N(R1)2 —CH═N—OH and —CH2SR1 radicals wherein R is a C1 to C10 alkyl, phenyl or benzyl and R1 is R or hydrogen; or a pharmaceutically acceptable salt thereof
    • 一种治疗眼低血压,高血压,出血,心肌缺血,心绞痛,冠状动脉收缩,蛛网膜下腔出血后脑血管收缩,脑出血和哮喘的方法,其包括向患有其的哺乳动物施用治疗有效量的作为化合物的血栓烷配体 式I,其中Y是(CH 2)x; Z选自O,OCH 2和(CR 2)x,x为1或2的整数; n为0或1; R2是氢或1至4个碳的烷基; A是具有2-7个碳原子的亚烷基或亚烯基,该基团可以被一个或多个羟基,氧代,烷氧基或烷基羧基取代,或者所述亚烷基或亚烯基可以具有一个或多个链烯氧基或亚氨基; B是具有3至7个碳原子的甲基或环烷基,或选自烃基芳基和杂芳基的芳基,其中杂原子选自氮,氧和硫原子, 或所述甲基,环烷基或芳基的取代衍生物,其中所述取代基选自卤素,硝基,氨基,硫醇,羟基,烷氧基和烷基羧基; 并且X选自硝基,氰基,-COOR,-CH 2 OR 1,-C(O)N(R 1)2,-CH 2 N(R 1)2 -CH = N-OH和-CH 2 S R 1基团,其中R为 C1至C10烷基,苯基或苄基,R1为R或氢; 或其药学上可接受的盐
    • 3. 发明授权
    • Stereoselective process for alkyl phenylglycolic acids
    • 烷基苯基乙醇酸的立体选择性方法
    • US06376684B1
    • 2002-04-23
    • US09711776
    • 2000-11-13
    • Chris Hugh SenanayakePaul T. Grover
    • Chris Hugh SenanayakePaul T. Grover
    • C07D30793
    • C07D317/34C07C51/353C07C59/54
    • A process for preparing an alkyl phenylglycolic acid is disclosed. It follows the sequence of condensing a substituted acetaldehyde with mandelic acid to provide a 5-phenyl-1,3-dioxolan-4-one, which is condensed with an alkyl ketone or aldehyde to provide a 5-(1-hydroxyalkyl)-5-phenyl-1,3-dioxolan-4-one, which is dehydrated to a 5-(1-alkenyl)-5-phenyl-1,3-dioxolan-4-one. The 5-(1-alkenyl)-5-phenyl-1,3-dioxolan-4-one may be hydrolyzed and reduced to an &agr;-alkylphenylglycolic acid or the hydrolysis and reduction steps may be reversed. The process enables the production of single enantiomers of cyclohexylphenylglycolic acid (CHPGA). An analogous process for racemic CHPGA is disclosed employing racemic mandelic acid and acetone. Novel intermediates in the process are also disclosed.
    • 公开了一种制备烷基苯基乙醇酸的方法。 它遵循将取代的乙醛与扁桃酸缩合的顺序,得到5-烷基酮或醛缩合的5-苯基-1,3-二氧戊环-4-酮,得到5-(1-羟基烷基)-5 - 苯基-1,3-二氧戊环-4-酮,将其脱水至5-(1-烯基)-5-苯基-1,3-二氧戊环-4-酮。 可以将5-(1-烯基)-5-苯基-1,3-二氧戊环-4-酮水解并还原成α-烷基苯基乙醇酸,或者可以逆转水解和还原步骤。 该方法能够生产环己基苯基乙醇酸(CHPGA)的单一对映异构体。 公开了外消旋CHPGA的类似方法,其使用外消旋扁桃酸和丙酮。 还公开了该方法中的新型中间体。
    • 6. 发明授权
    • Method for isolating terpene trilactones (ginkgolides, bilobalide) from leaves and pharmaceutical powders of ginkgo biloba
    • 从叶片和银杏叶药物粉末中分离萜内三聚物(银杏内酯,银杏内酯)的方法
    • US06590109B2
    • 2003-07-08
    • US10194089
    • 2002-07-11
    • Dirk LichtblauNina BerovaJohn BergerKoji Nakanishi
    • Dirk LichtblauNina BerovaJohn BergerKoji Nakanishi
    • C07D30793
    • C07D307/77A61K31/365A61K36/16
    • A method of isolating terpene trilactones from Ginkgo biloba plant material or extract comprising the steps of suspending the plant material or extract in either water or an aqueous solution of an oxidation reagent; extracting the terpene trilactones using an acceptable extraction agent; separating the organic layer from the aqueous layer; washing the organic layer with an acceptable aqueous salt or hydroxide solution, which may be an alkaline solution; and drying the organic layer to form a dried extract containing terpene trilactones. Further purification by treatment with or filtration over activated charcoal, by treatment with or filtration over alumina and by recrystallization with an acceptable solvent or solvent mixture leads to extracts with a content of terpene trilactones higher than 50%. Unwanted levels of ginkgolic acids are reduced to acceptable levels by reversed phase chromatography.
    • 从银杏植物材料或提取物中分离萜品三内酯的方法,包括将植物材料或提取物悬浮在水或氧化试剂的水溶液中的步骤; 使用可接受的提取剂萃取萜烯三内酯; 从水层分离有机层; 用可接受的盐或氢氧化物溶液洗涤有机层,其可以是碱性溶液; 并干燥有机层以形成含有萜烯三内酯的干燥提取物。 通过用活性炭处理或过滤进一步纯化,通过在氧化铝上处理或过滤,并用可接受的溶剂或溶剂混合物重结晶,得到萜烯三内酯的含量高于50%的提取物。 不需要的银杏酸水平通过反相色谱法降至可接受的水平。